- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.11.25 | Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes | ||
| 24.11.25 | Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone | ||
| 24.11.25 | Gilead hatches $400M biobucks deal for Swedish biotech's TREX1 cancer program | ||
| 24.11.25 | Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission | ||
| 24.11.25 | J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2 | ||
| 24.11.25 | Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class | ||
| 21.11.25 | In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation | ||
| 21.11.25 | FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process | ||
| 20.11.25 | Moderna's reshaping rolls on with 3 more pipeline purges | ||
| 20.11.25 | Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3 | ||
| 20.11.25 | Ensoma halves workforce after transitioning genetic medicine to the clinic | ||
| 20.11.25 | Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach | ||
| 20.11.25 | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| 19.11.25 | Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO | ||
| 19.11.25 | Celltrion still thinking bigger than biosimilars with option for $350M antibody deal | ||
| 19.11.25 | Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir | ||
| 19.11.25 | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| 19.11.25 | GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space | ||
| 18.11.25 | How Biogen is returning to its roots with a West Coast immunology outpost | ||
| 18.11.25 | Vanda tackles Wegovy-driven vomiting, sparking race to phase 3 | ||
| 18.11.25 | Jefferies' London conference cements reputation as 'JP Morgan for Europe' | ||
| 18.11.25 | Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial | ||
| 17.11.25 | Genmab sheds another clinical ADC from $1.8B ProfoundBio buy | ||
| 17.11.25 | Repare finds fix as biotech agrees to XenoTherapeutics buyout | ||
| 17.11.25 | Bayer opens Beijing incubator and names initial occupants, tightening ties to China |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .